DCG IV (cas# 147782-19-2) is a useful research chemical.DCG IV is a group-II metabotropic glutamate (mGlu) receptor agonist. DCG-IV protected mouse cortical neurons grown in mixed cultures against excitotoxic degeneration induced by a 10 min pulse with NMDA.
Presynaptic depressant; highly potent agonist for group II mGlu receptors. Also available as part of the Group II mGlu Receptor Tocriset™ and Mixed mGlu Receptor Tocriset™ .
DCG-IV (1-10 mg/kg; i.p.) depresses the phencyclidine (PCP)-induced hyperlocomotion[4].
| Animal Model: | Male ICR mice weighing about 40 g (PCP-induced locomotor activity)[4] |
| Dosage: | 10, 5, or 1 mg/kg |
| Administration: | I.p. |
| Result: | Reduced spontaneous activities of the animals at 10 or 5 mg/kg.
|
mGluR2R: 0.35 μM (EC50); mGluR3R: 0.09 μM (EC50); mGluR1R: 389 μM (IC50); mGluR5: 630 μM (IC50); mGluR4R: 22.5 μM (IC50); mGluR6: 39.6 μM (IC50); mGluR7: 40.1 μM (IC50); mGluR8: 32 μM (IC50)
